Elena Myasoedova, M.D., Ph.D.

The purpose of this study is to create a biorepository of biosamples from patients with rheumatoid arthritis (RA) in sustained remission. Identifying biomarkers associated with failure vs success of immunosuppressive treatments (DMARD) tapering is a critical need which will allow to maximize the benefits and safety of available treatments.

The purpose of this study is to create a biorepository of biosamples from patients with psoriatic arthritis (PsA). This biorepository will enable future investigation of biomarkers associated with PsA.

The purpose of this study is to create a biobank with a linked database including medical data and biospecimens from adult (>18 years) patients with rheumatoid arthritis (RA) and individuals with positive cyclic citrullinated peptide antibodies (anti-CCPantibodies) who do not yet meet classification criteria for RA (i.e. pre-RA), as well as comparators without RA.  We propose to recruit and enroll 1,500 participants with RA and pre-RA and 1500 participants without RA.  

Study objective: Define pharmacogenomics markers and clinical phenotype features associated with response to RA treatments. Using electronical medical records data and a blood draw with DNA for genotyping from prospectively recruited patients seen in rheumatology clinic (n=100), we will identify genomic markers and leading phenotype features of responders to routinely used anti-rheumatic medications at 3 and 6 months of treatment based on disease activity score with 28-joint count (DAS28), accounting for socioeconomic factors, comorbidities, RA characteristics and prior anti-rheumatic medication use. We hypothesize that: Patients responding to antirheumatic medication(s) and their combinations share similar phenotype and/or genomic markers.